Farewell to Chris Richardson

Chris Richardson joined the lab as a Postdoctoral Fellow in July 2014 and made huge advances in human gene editing. He developed new ways to improve NHEJ and HDR, plus discovered out that genome editing in human cells works via the Fanconi Anemia Pathway. Three major first author papers in three years – not bad! Chris will be joining Spotlight Therapeutics as a Group Leader, and may have some additional career news to share soon. We wish you success in all your future endeavors!

SUBMIT A COMMENT

Your email address will not be published. Required fields are marked *

Filters

Please select

Latest News

February 26, 2025

Welcome to Rafaela!

Rafaela received her Master’s degree in Bioengineering from the University of Engineering of Porto in 2019, where she worked on the production and characterization...

February 24, 2025

Welcome to Boris!

Boris Korablev received his Bachelor’s degree in Molecular and Cell Biology from UC Berkeley in 2021. Before joining ETH, he worked at a gene-editing...

January 30, 2025

C-TERMINAL AMIDES FUNCTION AS SIGNALS FOR PROTEIN DEGRADATION- PUBLISHED IN NATURE

Proteins are essential building blocks of life, but they can become toxic to our cells if damaged, for example under oxidative stress. In turn, human cells ...

News Archive

Tweets